Novimmune appoints Adrian Mills as Chief Business Officer

Also becomes a member of the Executive Committee

Swiss antibody based drug developer Novimmune has appointed Adrian Mills as Chief Business Officer and a member of the Executive Committee. He will lead the company's commercial development activities, as well as business development.

David Slack, Head of Corporate and Business Development, is leaving Novimmune to focus on opportunities outside the company.

Mills brings to the role more than 20 years of experience as a pharmaceutical executive with a particular focus on the commercialisation of orphan drugs.

He has joined Novimmune from GlaxoSmithKline, where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently he was European Commercial Director for Rare and Critical Diseases.

Prior to GSK, Mills worked in management consulting and investment banking in the life sciences sector.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now